These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12417456)

  • 1. Motivation, reward, and Parkinson's disease: influence of dopatherapy.
    Czernecki V; Pillon B; Houeto JL; Pochon JB; Levy R; Dubois B
    Neuropsychologia; 2002; 40(13):2257-67. PubMed ID: 12417456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?
    Czernecki V; Pillon B; Houeto JL; Welter ML; Mesnage V; Agid Y; Dubois B
    J Neurol Neurosurg Psychiatry; 2005 Jun; 76(6):775-9. PubMed ID: 15897497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease.
    Funkiewiez A; Ardouin C; Cools R; Krack P; Fraix V; Batir A; Chabardès S; Benabid AL; Robbins TW; Pollak P
    Mov Disord; 2006 Oct; 21(10):1656-62. PubMed ID: 16830317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.
    van Nuland AJ; Helmich RC; Dirkx MF; Zach H; Toni I; Cools R; den Ouden HEM
    Brain; 2020 Dec; 143(11):3422-3434. PubMed ID: 33147621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
    Funkiewiez A; Ardouin C; Krack P; Fraix V; Van Blercom N; Xie J; Moro E; Benabid AL; Pollak P
    Mov Disord; 2003 May; 18(5):524-30. PubMed ID: 12722166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine modulates striatal response to reward and punishment in patients with Parkinson's disease: a pharmacological challenge fMRI study.
    Argyelan M; Herzallah M; Sako W; DeLucia I; Sarpal D; Vo A; Fitzpatrick T; Moustafa AA; Eidelberg D; Gluck M
    Neuroreport; 2018 May; 29(7):532-540. PubMed ID: 29432300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine is associated with prioritization of reward-associated memories in Parkinson's disease.
    Sharp ME; Duncan K; Foerde K; Shohamy D
    Brain; 2020 Aug; 143(8):2519-2531. PubMed ID: 32844197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-demented Parkinson's disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes.
    Martinez-Horta S; Sampedro F; Pagonabarraga J; Fernandez-Bobadilla R; Marin-Lahoz J; Riba J; Kulisevsky J
    Brain Imaging Behav; 2017 Oct; 11(5):1334-1342. PubMed ID: 27730477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
    Pérez-Pérez J; Pagonabarraga J; Martínez-Horta S; Fernández-Bobadilla R; Sierra S; Pascual-Sedano B; Gironell A; Kulisevsky J
    Drugs Aging; 2015 May; 32(5):401-7. PubMed ID: 25941103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease.
    Evans AH; Lawrence AD; Lees AJ
    J Neurol Neurosurg Psychiatry; 2009 Mar; 80(3):267-72. PubMed ID: 18977820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
    Shohamy D; Myers CE; Grossman S; Sage J; Gluck MA
    Behav Brain Res; 2005 Jan; 156(2):191-9. PubMed ID: 15582105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. It's all in the type of the task: Dopamine modulates kinematic patterns during competitive vs. cooperative interaction in Parkinson's disease.
    Straulino E; Scaravilli T; Bulgheroni M; D'Amico E; Castiello U
    Neuropsychologia; 2016 Dec; 93(Pt A):106-115. PubMed ID: 27756693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication.
    Swainson R; Rogers RD; Sahakian BJ; Summers BA; Polkey CE; Robbins TW
    Neuropsychologia; 2000; 38(5):596-612. PubMed ID: 10689037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.
    Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
    Behav Brain Res; 2012 Apr; 230(1):116-24. PubMed ID: 22343069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
    van Eimeren T; Ballanger B; Pellecchia G; Miyasaki JM; Lang AE; Strafella AP
    Neuropsychopharmacology; 2009 Dec; 34(13):2758-66. PubMed ID: 19741594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine enhances willingness to exert effort for reward in Parkinson's disease.
    Chong TT; Bonnelle V; Manohar S; Veromann KR; Muhammed K; Tofaris GK; Hu M; Husain M
    Cortex; 2015 Aug; 69():40-6. PubMed ID: 25967086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
    Lange KW; Paul GM; Naumann M; Gsell W
    J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reward processing dysfunction in ventral striatum and orbitofrontal cortex in Parkinson's disease.
    du Plessis S; Bossert M; Vink M; van den Heuvel L; Bardien S; Emsley R; Buckle C; Seedat S; Carr J
    Parkinsonism Relat Disord; 2018 Mar; 48():82-88. PubMed ID: 29307561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.